IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization
Insight Molecular Diagnostics (IMDX) reported Q1 2026 revenues of approximately $32,000, primarily from laboratory services at its Tennessee facility. The company remains pre-revenue for its kitted clinical assay. IMDX has made progress toward commercializing GraftAssureDx, with productive dialogue with the FDA and a target for marketing authorization later in 2026. A Northeast kidney transplant center, among the top 10 in the U.S., has signed a clinical trial agreement to participate in the GALACTIC study.
Key figures
- Eps Beat
- 0
- Revenue
- 32000
- Revenue Yoy
- -98.5%
- Net loss
- 4290000
- Cash balance
- 29355000
- Gross profit
- 15000
- Non gaap net loss
- 9593000
- Operating expenses
- 4428000
- Adjusted ebitda loss
- 9085000
- Sales and marketing expenses
- 2402000
- Research and development expenses
- 4953000
- General and administrative expenses
- 2991000
- Weighted average shares outstanding
- 34519000
- Pro forma fully weighted share count
- 36700000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.